Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America

Becky L. Genberg, Ira B. Wilson, David Bangsberg, Julia Arnsten, Kathy Goggin, Robert H. Remien, Jane Simoni, Robert Gross, Nancy Reynolds, Marc Rosen, Honghu Liu

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objective: Adherence to antiretroviral therapies (ART) is the strongest predictor of viral suppression among individuals infected with HIV, however, limited data exists to understand the patterns of adherence that confer the greatest benefit across different ART regimens. Design: Longitudinal data pooled from 16 studies conducted between 1997 and 2009 across the United States. Methods: Adherence was measured using Medication Event Monitoring System. Percentage of time with sufficient drug concentrations (covered time) and the length of the longest treatment interruption during the 28 days prior to plasma HIV-RNA measurements were calculated. Logistic regression with generalized estimating equations was used to estimate medication-specific adherence estimates on detectable HIV-RNA (>400 copies/ml). Results: One thousand and eighty-eight participants with 3795 HIV-RNA measures were studied. Both lower covered time and greater longest interruption showed dose-response relationships with the odds of detectable HIV-RNA; however, estimates did not vary by medication regimen. Compared with 93-100% coverage, periods of 0-25% covered time had a three-fold increased risk of detectable HIV-RNA [odds ratio (OR) = 3.22, 95% confidence interval (CI): 2.48-4.19]. Similarly, compared to longest interruptions of 0-48 h, longest interruptions of 21-28 days had a nearly four-fold increased risk of detectable HIV-RNA (OR = 3.65, 95% CI: 2.77, 4.81). Conclusion: We found that adherence was consistently strongly associated with treatment response across ART regimens. Of the patterns of adherence, longer interruptions may have greater impact than covered time. Future research should investigate additional methods for examining adherence patterns, understanding the determinants of consecutive missed doses and the evaluation of interventions designed to address interruptions in treatment.

Original languageEnglish (US)
Pages (from-to)1415-1423
Number of pages9
JournalAIDS
Volume26
Issue number11
DOIs
StatePublished - Jul 17 2012
Externally publishedYes

Fingerprint

North America
HIV
RNA
Therapeutics
Odds Ratio
Confidence Intervals
Medication Adherence
Logistic Models
Pharmaceutical Preparations

Keywords

  • antiretroviral therapy
  • medication adherence
  • protease inhibitors
  • reverse transcriptase inhibitors
  • viral load

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Genberg, B. L., Wilson, I. B., Bangsberg, D., Arnsten, J., Goggin, K., Remien, R. H., ... Liu, H. (2012). Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS, 26(11), 1415-1423. https://doi.org/10.1097/QAD.0b013e328354bed6

Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. / Genberg, Becky L.; Wilson, Ira B.; Bangsberg, David; Arnsten, Julia; Goggin, Kathy; Remien, Robert H.; Simoni, Jane; Gross, Robert; Reynolds, Nancy; Rosen, Marc; Liu, Honghu.

In: AIDS, Vol. 26, No. 11, 17.07.2012, p. 1415-1423.

Research output: Contribution to journalArticle

Genberg, BL, Wilson, IB, Bangsberg, D, Arnsten, J, Goggin, K, Remien, RH, Simoni, J, Gross, R, Reynolds, N, Rosen, M & Liu, H 2012, 'Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America', AIDS, vol. 26, no. 11, pp. 1415-1423. https://doi.org/10.1097/QAD.0b013e328354bed6
Genberg, Becky L. ; Wilson, Ira B. ; Bangsberg, David ; Arnsten, Julia ; Goggin, Kathy ; Remien, Robert H. ; Simoni, Jane ; Gross, Robert ; Reynolds, Nancy ; Rosen, Marc ; Liu, Honghu. / Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. In: AIDS. 2012 ; Vol. 26, No. 11. pp. 1415-1423.
@article{7e520322597d47a392d4d8edceefb998,
title = "Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America",
abstract = "Objective: Adherence to antiretroviral therapies (ART) is the strongest predictor of viral suppression among individuals infected with HIV, however, limited data exists to understand the patterns of adherence that confer the greatest benefit across different ART regimens. Design: Longitudinal data pooled from 16 studies conducted between 1997 and 2009 across the United States. Methods: Adherence was measured using Medication Event Monitoring System. Percentage of time with sufficient drug concentrations (covered time) and the length of the longest treatment interruption during the 28 days prior to plasma HIV-RNA measurements were calculated. Logistic regression with generalized estimating equations was used to estimate medication-specific adherence estimates on detectable HIV-RNA (>400 copies/ml). Results: One thousand and eighty-eight participants with 3795 HIV-RNA measures were studied. Both lower covered time and greater longest interruption showed dose-response relationships with the odds of detectable HIV-RNA; however, estimates did not vary by medication regimen. Compared with 93-100{\%} coverage, periods of 0-25{\%} covered time had a three-fold increased risk of detectable HIV-RNA [odds ratio (OR) = 3.22, 95{\%} confidence interval (CI): 2.48-4.19]. Similarly, compared to longest interruptions of 0-48 h, longest interruptions of 21-28 days had a nearly four-fold increased risk of detectable HIV-RNA (OR = 3.65, 95{\%} CI: 2.77, 4.81). Conclusion: We found that adherence was consistently strongly associated with treatment response across ART regimens. Of the patterns of adherence, longer interruptions may have greater impact than covered time. Future research should investigate additional methods for examining adherence patterns, understanding the determinants of consecutive missed doses and the evaluation of interventions designed to address interruptions in treatment.",
keywords = "antiretroviral therapy, medication adherence, protease inhibitors, reverse transcriptase inhibitors, viral load",
author = "Genberg, {Becky L.} and Wilson, {Ira B.} and David Bangsberg and Julia Arnsten and Kathy Goggin and Remien, {Robert H.} and Jane Simoni and Robert Gross and Nancy Reynolds and Marc Rosen and Honghu Liu",
year = "2012",
month = "7",
day = "17",
doi = "10.1097/QAD.0b013e328354bed6",
language = "English (US)",
volume = "26",
pages = "1415--1423",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America

AU - Genberg, Becky L.

AU - Wilson, Ira B.

AU - Bangsberg, David

AU - Arnsten, Julia

AU - Goggin, Kathy

AU - Remien, Robert H.

AU - Simoni, Jane

AU - Gross, Robert

AU - Reynolds, Nancy

AU - Rosen, Marc

AU - Liu, Honghu

PY - 2012/7/17

Y1 - 2012/7/17

N2 - Objective: Adherence to antiretroviral therapies (ART) is the strongest predictor of viral suppression among individuals infected with HIV, however, limited data exists to understand the patterns of adherence that confer the greatest benefit across different ART regimens. Design: Longitudinal data pooled from 16 studies conducted between 1997 and 2009 across the United States. Methods: Adherence was measured using Medication Event Monitoring System. Percentage of time with sufficient drug concentrations (covered time) and the length of the longest treatment interruption during the 28 days prior to plasma HIV-RNA measurements were calculated. Logistic regression with generalized estimating equations was used to estimate medication-specific adherence estimates on detectable HIV-RNA (>400 copies/ml). Results: One thousand and eighty-eight participants with 3795 HIV-RNA measures were studied. Both lower covered time and greater longest interruption showed dose-response relationships with the odds of detectable HIV-RNA; however, estimates did not vary by medication regimen. Compared with 93-100% coverage, periods of 0-25% covered time had a three-fold increased risk of detectable HIV-RNA [odds ratio (OR) = 3.22, 95% confidence interval (CI): 2.48-4.19]. Similarly, compared to longest interruptions of 0-48 h, longest interruptions of 21-28 days had a nearly four-fold increased risk of detectable HIV-RNA (OR = 3.65, 95% CI: 2.77, 4.81). Conclusion: We found that adherence was consistently strongly associated with treatment response across ART regimens. Of the patterns of adherence, longer interruptions may have greater impact than covered time. Future research should investigate additional methods for examining adherence patterns, understanding the determinants of consecutive missed doses and the evaluation of interventions designed to address interruptions in treatment.

AB - Objective: Adherence to antiretroviral therapies (ART) is the strongest predictor of viral suppression among individuals infected with HIV, however, limited data exists to understand the patterns of adherence that confer the greatest benefit across different ART regimens. Design: Longitudinal data pooled from 16 studies conducted between 1997 and 2009 across the United States. Methods: Adherence was measured using Medication Event Monitoring System. Percentage of time with sufficient drug concentrations (covered time) and the length of the longest treatment interruption during the 28 days prior to plasma HIV-RNA measurements were calculated. Logistic regression with generalized estimating equations was used to estimate medication-specific adherence estimates on detectable HIV-RNA (>400 copies/ml). Results: One thousand and eighty-eight participants with 3795 HIV-RNA measures were studied. Both lower covered time and greater longest interruption showed dose-response relationships with the odds of detectable HIV-RNA; however, estimates did not vary by medication regimen. Compared with 93-100% coverage, periods of 0-25% covered time had a three-fold increased risk of detectable HIV-RNA [odds ratio (OR) = 3.22, 95% confidence interval (CI): 2.48-4.19]. Similarly, compared to longest interruptions of 0-48 h, longest interruptions of 21-28 days had a nearly four-fold increased risk of detectable HIV-RNA (OR = 3.65, 95% CI: 2.77, 4.81). Conclusion: We found that adherence was consistently strongly associated with treatment response across ART regimens. Of the patterns of adherence, longer interruptions may have greater impact than covered time. Future research should investigate additional methods for examining adherence patterns, understanding the determinants of consecutive missed doses and the evaluation of interventions designed to address interruptions in treatment.

KW - antiretroviral therapy

KW - medication adherence

KW - protease inhibitors

KW - reverse transcriptase inhibitors

KW - viral load

UR - http://www.scopus.com/inward/record.url?scp=84863698764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863698764&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328354bed6

DO - 10.1097/QAD.0b013e328354bed6

M3 - Article

VL - 26

SP - 1415

EP - 1423

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 11

ER -